This conjugate was based on their discovery that oncogenic KRAS signaling induces early ferrous iron (Fe2+) accumulation throughout mutant KRAS, allowing selective blockage of MAPK and targeting of KRAS-driven solid tumors.652 This groundbreaking research demonstrates the potential for utilizing conjugates as carriers to target previously undruggable proteins, offering new hope for cancer treatment. Here, KRAS is linked to cancer.